Health
WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products
* WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP manufacturing for microbial-derived products. HANGZHOU, China, July 4, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing ...
2022-07-05 08:30
2388
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia
This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs inChina. ARVN003 is expected to be the first approved drug for presbyopia inChina. SHANGHAI, July 4, 2022 /PRNew...
2022-07-04 22:14
2404
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...
2022-07-04 13:34
2057
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment ofPaul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," s...
2022-07-01 22:00
5096
Bon Natural Life Limited Announces Change to Board Composition
XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment ofJeffrey Guzy, as a new independent Director to i...
2022-07-01 04:30
3295
Fosun's Businesses Shows Strong Recovery Momentum as Consumption Regains Vitality and Tourism Industry Continues to Recover
HONG KONG, June 30, 2022 /PRNewswire/ -- The Bund Finance Center (BFC) in Shanghai officially resumed dine-in services at restaurants starting from 29 June. At present, Fosun's businesses and shopping centers inShanghai, including the BFC, Yuyuan Tourist Mart, Forte Woli City, and Orstar City Zhe...
2022-06-30 20:16
3911
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm...
2022-06-30 10:41
1730
Infobird Co., Ltd Provides Digital and Intelligent Customer Engagement Solution to Enhance Patient Vaccination Notification Services for a Top-10 Global Pharmaceutical Company's Subsidiary
BEIJING, June 29, 2022 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ: IFBD) ("Infobird" or the "Company"), a leading provider of AI-powered customer engagement solutions inChina, today announced that it has started to provide services to a leading global pharmaceutical and vaccine manufacturer's sub...
2022-06-29 20:30
2052
Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
* Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing * China's first immunotherapy bi-specific antibody approved for marketing * A phase III trial of Cadonilimab combined with platinum-based chemotherapy +/- bevacizumab for the first-line treatment ...
2022-06-29 20:14
1986
Supporting Communities and Sharing Happiness, 28 Liberty Successfully Hosts Multiple Community Events at New York's Fosun Plaza
NEW YORK, June 28, 2022 /PRNewswire/ -- As the summer arrives, New Yorkers have been enjoying their favorite season in the year. Starting from early June, in just 3 weeks, Fosun's 28 Liberty has successfully hosted multiple community events at Fosun Plaza with thousands of participants, in suppor...
2022-06-29 09:00
1765
iNtRON to Seek a New Clinical Partner for SAL200 Endolysin
* TONABACASE, the first registered INN by WHO for Endolysin * First-in-Class Endolysin-based Drug against Superbugs * US FDA Phase 2 IND Approval for TONABACASE, SAL200 * Roivant has returned the rights for the asset just before the first patient injection BOSTON and SEOUL, South Korea, Jun...
2022-06-28 21:00
1703
Sanofi Enters into a Partnering Agreement with Health2Sync
Paving the Way for Digital Therapeutics in Diabetes TAIPEI and TOKYO, June 27, 2022 /PRNewswire/ -- Sanofi K.K. (Head office: Shinjuku-ku,Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync. (Head office: Taito-ku,Tokyo; CEO: Ed Deng) have entered into a partnering agreement ...
2022-06-28 11:00
1932
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the B7H4x4-1BB bispecific antibody (HBM7008), whi...
2022-06-27 19:04
2402
Amcor Lift-Off initiative shortlists start-ups for seed funding
ZURICH, June 27, 2022 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced the next phase of its inauguralAmcor Lift-Off initiative. Announced in April, Amcor Lift-Off is part of the organization's global innova...
2022-06-27 17:03
2018
Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application
SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance nu...
2022-06-26 08:00
3667
Sanyou Biopharmaceuticals forged strategic partnership with Dragon Sail Pharmaceutical to upgrade integrated innovative antibody drug R&D
SHANGHAI, June 24, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, aCDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture servic...
2022-06-25 08:00
4994
Stryker's debut at World Intelligence Congress: Bringing Stryker's Advanced Digital Healthcare to China
SHANGHAI, June 24, 2022 /PRNewswire/ -- Stryker (NYSE:SYK), a leading medical technologies company, attended the 6th World Intelligence Congress (WIC) in China, showcasing how its Advanced Digital Healthcare solutions brings clinical, operational and financial values for the healthcare market. Th...
2022-06-24 23:00
5701
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patients with idiopathic pulmonary fibrosis - Daewoong Pharmaceutical to start a multinational phase 2 clinical trial for DWN12088 in September SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong...
2022-06-24 21:00
3580
USANA Malaysia Named No. 1 Combination Dietary Supplements Brand by Euromonitor International
Euromonitor International honors USANA Malaysia for fourth year in a row KUALA LUMPUR, Malaysia, June 24, 2022 /PRNewswire/ -- USANA Malaysia was recently recognized as a top brand by market research giant Euromonitor International. Awarded the title No. 1 Combination Dietary Supplements Brand in...
2022-06-24 10:00
5790
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicin...
2022-06-23 23:00
2362
Week's Top Stories
Most Reposted
Infobip recognized as RCS Business Messaging Leader by Juniper Research
[Picked up by 331 media titles]
2024-11-05 18:06
Mastercard goes OTP-free in APAC for faster, safer online transactions
[Picked up by 326 media titles]
2024-11-06 09:00Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Mastercard launches Pay Local, enabling Asia's digital wallet providers to process card payments from more than 2 billion Mastercard cardholders
[Picked up by 317 media titles]
2024-11-05 09:00XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
[Picked up by 277 media titles]
2024-11-07 11:34
Most Read
Mastercard goes OTP-free in APAC for faster, safer online transactions
2024-11-06 09:00
12399
Infobip recognized as RCS Business Messaging Leader by Juniper Research
2024-11-05 18:06
9442
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
8852